Randomized clinical trials have defined the survival advantage with the addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer (mCRC). Under representation of Hispanics contributes to poorly defined outcomes in this group. We aim to determine whether the real-world benefit of biologics extends to Hispanics using a comparative effectiveness research approach. This retrospective cohort study included all treatment centers contributing to SEER registry with available claims in the SEER-Medicare linked database (2001-2011) and 2 hospitals (2004-2016) catering to minorities. Metastatic CRC patients were The primary outcome was overall survival (OS) among the Hispanic patients calculated from time of administration of first dose of chemotherapy to death or last follow-up. A weighted Cox regression model was used to assess differences in survival. We identified 182 Hispanic patients with mCRC from the Patient Entitlement and Diagnosis Summary (PEDSF) file (n = 101) and hospital database (n = 81). Overall, 52% were women and 72% received biologics. The median OS was 11.3 and 17.0 months in chemotherapy and biochemotherapy group, respectively. Biochemotherapy offered a survival benefit compared with chemotherapy alone, with an average hazard rate reduction of 39% (95% CI 6%-60%, = .0236) using inverse probability of treatment weighting (IPTW) based analysis. In this cohort of Hispanic patients with mCRC, biochemotherapy was associated with longer survival. Clinicians may offer biochemotherapy therapy to all patients regardless of race/ethnicity to maximize clinical benefit.

中文翻译：

---

生物制剂对西班牙裔转移性结直肠癌患者的有效性

随机临床试验已经确定了转移性结直肠癌 (mCRC) 患者在化疗中添加生物药物的生存优势。西班牙裔代表性不足导致该群体的结果不明确。我们的目标是使用比较有效性研究方法来确定生物制剂的现实益处是否延伸到西班牙裔。这项回顾性队列研究包括所有参与 SEER 登记并在 SEER-Medicare 链接数据库（2001-2011 年）中提供索赔的治疗中心以及 2 家为少数族裔提供服务的医院（2004-2016 年）。转移性结直肠癌患者的主要结局是西班牙裔患者的总生存期（OS），从第一次化疗的给药时间到死亡或最后一次随访的时间计算。使用加权 Cox 回归模型来评估生存差异。我们从患者权利和诊断摘要 (PEDSF) 文件 (n = 101) 和医院数据库 (n = 81) 中确定了 182 名西班牙裔 mCRC 患者。总体而言，52% 是女性，72% 接受了生物制剂。化疗组和生物化疗组的中位 OS 分别为 11.3 个月和 17.0 个月。与单独化疗相比，生物化疗提供了生存获益，使用基于治疗权重逆概率 (IPTW) 的分析，平均风险率降低了 39% (95% CI 6%-60%, = .0236)。在这组患有转移性结直肠癌的西班牙裔患者中，生物化疗与更长的生存期相关。临床医生可以为所有患者提供生物化疗治疗，无论种族/民族如何，以最大限度地提高临床效益。